| Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM (NCT00262730) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2006-01-01 |
| Safety and Efficacy of Talampanel in Glioblastoma Multiforme (NCT00267592) | Teva Branded Pharmaceutical Products R&D, Inc. | 2005-12-01 |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas (NCT00751270) | Candel Therapeutics, Inc. | 2005-11-01 |
| A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma (NCT00792012) | University of Colorado, Denver | 2005-11-01 |
| Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme (NCT00112502) | M.D. Anderson Cancer Center | 2005-09-01 |
| GW572016 to Treat Recurrent Malignant Brain Tumors (NCT00107003) | National Cancer Institute (NCI) | 2005-03-30 |
| Chloroquine for Treatment of Glioblastoma Multiforme (NCT00224978) | National Institute of Neurology and Neurosurgery, Mexico | 2005-01-01 |
| Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation (NCT03225300) | Taichung Veterans General Hospital | 2005-01-01 |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors (NCT00104091) | Teva Branded Pharmaceutical Products R&D, Inc. | 2004-12-01 |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma (NCT00114309) | TransMolecular | 2004-11-01 |
| Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) (NCT00093964) | EMD Serono | 2004-10-13 |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma (NCT00154375) | Novartis Pharmaceuticals | 2004-10-01 |
| Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors (NCT00187486) | University of California, San Francisco | 2004-08-01 |
| Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM (NCT00508456) | M.D. Anderson Cancer Center | 2004-08-01 |
| IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma (NCT00089427) | INSYS Therapeutics Inc | 2004-07-01 |
| Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme (NCT00083512) | National Cancer Institute (NCI) | 2004-06-22 |
| Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme (NCT00083447) | Xenova Biomedix | 2004-05-01 |
| The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme (NCT00076986) | INSYS Therapeutics Inc | 2004-02-01 |
| Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) (NCT00116376) | Novartis Pharmaceuticals | 2004-01-01 |
| Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas (NCT00412542) | M.D. Anderson Cancer Center | 2003-10-01 |
| 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients (NCT00504660) | M.D. Anderson Cancer Center | 2003-09-01 |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas (NCT00062504) | Teva Branded Pharmaceutical Products R&D, Inc. | 2003-07-01 |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma (NCT00064779) | INSYS Therapeutics Inc | 2003-07-01 |
| Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme (NCT00050986) | M.D. Anderson Cancer Center | 2002-12-01 |
| Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma (NCT00613093) | Duke University | 2002-10-01 |
| Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas (NCT00031083) | Biogen | 2002-04-02 |
| Genetic Analysis of Brain Tumors (NCT00031538) | National Cancer Institute (NCI) | 2002-03-01 |
| Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme (NCT00038493) | M.D. Anderson Cancer Center | 2001-09-21 |
| Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients (NCT00024557) | INSYS Therapeutics Inc | 2001-06-01 |
| A Phase I/II Study of the Photon Radiosurgery System (NCT00179907) | Ann & Robert H Lurie Children's Hospital of Chicago | 2001-05-01 |
| Radiotherapy for Malignant Astrocytomas in the Elderly (NCT00430911) | Assistance Publique - Hôpitaux de Paris | 2001-02-01 |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma (NCT00024570) | INSYS Therapeutics Inc | 2000-11-01 |
| Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms (NCT00004688) | Emory University | 1996-08-01 |
| Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma (NCT03722355) | Radiation Therapy Oncology Group | 1990-11-09 |
| Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors (NCT00243490) | National Taiwan University Hospital | |
| Treatment of Recurrent GBM With APG-157 Via Expanded Access (NCT05551013) | Aveta Biomics, Inc. | |
| Expanded Access for Pembrolizumab (MK-3475) (NCT03311542) | Center Trials & Treatment | |
| Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) | Northwest Biotherapeutics | |
| Expanded Access to Gallium Maltolate (GaM) (NCT06404034) | Imaging Biometrics, LLC | |
| Expanded Access for KHK2455 (NCT04321694) | Kyowa Kirin, Inc. | |